http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2590666-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8d8266cbe5db70243c7576c8897ebe7
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2011-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c17ef57748e0aa55e23ec35bdff120b3
publicationDate 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2590666-A1
titleOfInvention Topical application of erythropoietin for the treatment of eye disorders and injuries
abstract The invention relates to the use of erythropoietin (EPO), in particular EPO in a pharmaceutical preparation, for the treatment of traumatized or diseased eyes, in particular the case of endothelial dysfunction or dystrophies of the eye, preferably in connection with mechanical or pathological injuries of the cornea and conditions related thereto, as well as injuries following eye surgery.
priorityDate 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409186
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395359
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409114
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281243
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445354
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280899

Total number of triples: 46.